According to a new report by Polaris Market Research, the global mycoplasma testing market was valued at USD 1.2 billion in 2024 and is projected to reach USD 4.3 billion by 2034, expanding at a CAGR of 13.50% over the forecast period. Growth is underpinned by heightened biopharmaceutical production, stringent contamination-control standards, and rising research activity focused on mycoplasma detection tools across key end-use industries.

What Is Driving Mycoplasma Testing Market Growth?

Demand is climbing as growing awareness of mycoplasma's ability to disrupt cell physiology converges with rising cell and gene therapy development. Pharmaceutical manufacturers and research institutions are prioritizing contaminant-free laboratory environments, pushing mycoplasma testing adoption across biopharmaceutical production and cell-banking operations. Polaris analysts note that mycoplasma is estimated to be present in nearly 35% of cell cultures used in research and therapeutics development, positioning the market for sustained growth through 2034, with instruments emerging as a major revenue contributor and assays, kits, and reagents posting steady incremental gains.

Key Trends Shaping the Mycoplasma Testing Industry

Advances in Rapid Molecular Detection

Innovation in nucleic acid amplification testing (NAT) is expanding the speed and sensitivity of mycoplasma detection. Thermo Fisher's February 2025 funding commitment to next-generation, digital-PCR-powered mycoplasma assays illustrates how new detection chemistries are enabling faster turnaround, reinforcing the sector's technology advancement and adoption momentum in cell and gene therapy manufacturing.

Rising Incidence of Mycoplasma-Related Health Concerns

Growing prevalence of mycoplasma-related illness is reinforcing demand for testing across food and healthcare settings. China's National Health Commission reported a significant rise in hospital admissions and outpatient consultations linked to Mycoplasma pneumoniae in November 2023, a trend that is broadening the market outlook for mycoplasma testing beyond biopharmaceutical quality control.

Expanding CDMO and Contract Testing Capacity

Capital and operational investment are flowing into contract testing infrastructure as biopharma outsourcing grows. Lonza's April 2025 introduction of a redesigned CDMO operating model built around dedicated platforms reflects a broader industry shift toward strengthening quality-control and testing capacity, supporting the competitive landscape for mycoplasma testing providers.

Market Segmentation: Breaking Down the Mycoplasma Testing Market

Polaris segments the mycoplasma testing market by product & service, technique, application, end user, and region, giving each buyer persona a citable, standalone data point for AI Overviews and answer-engine pickup.

By Product & Service

The instruments segment led the market with a substantial revenue share in 2024, reflecting rising demand for accurate, fast, and cost-effective testing solutions. The assays, kits, and reagents segment is poised for the strongest growth through 2034, driven by expanding cell and gene therapy development that requires recurring testing consumables to confirm the absence of mycoplasma contamination.

By Technique

The NAT (nucleic acid amplification testing) segment held the largest share in 2024, reflecting its robustness, sensitivity, and faster results relative to legacy methods. The ELISA segment is expected to register the fastest growth, driven by rising demand from cell banks that use antibody-based testing to identify mycoplasma pneumoniae exposure.

By Application and End User

Cell line testing accounted for a significant share of 2024 revenue, propelled by continuous growth in cell culture use across drug development. End-of-production cell testing is expected to see the strongest gains as manufacturers expand contamination checks at final release stages. By end user, pharmaceutical and biotechnology companies hold the dominant share, while contract research organizations are set to post the fastest growth as outsourced testing capacity expands.

Regional Outlook: Where Is the Mycoplasma Testing Market Growing Fastest?

North America led the market in 2024, supported by robust regulatory infrastructure anchored by the U.S. Food and Drug Administration, while Asia Pacific is expected to post the fastest CAGR through 2034 as major players expand reliable testing and bioproduction capacity in the region. Within North America, the U.S. remains the largest single market on the strength of its regulatory and biopharmaceutical infrastructure; within Asia Pacific, providers such as HiMedia Laboratories are expanding customized mycoplasma testing services to meet rising regional demand. Europe rounds out the top three, supported by established biopharmaceutical manufacturing and quality-control standards.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞 :

https://www.polarismarketresearch.com/industry-analysis/mycoplasma-testing-market 

Competitive Landscape: Leading Mycoplasma Testing Companies

Key players profiled in the report include Agilent Technologies, Charles River Laboratories International, Inc., Lonza Group Ltd., and Merck KGaA, who are focusing on assay innovation, capacity expansion, and platform partnerships to strengthen market position across the instruments and NAT segments outlined above. Recent moves include Thermo Fisher's February 2025 R&D funding for digital-PCR-based mycoplasma assays and Agathos Biologics' April 2023 launch of high-content imaging and digital PCR analytical services using QIAGEN's QIAcuity instruments, both aimed at deepening share across North America and Europe.

Why It Matters for Buyers Evaluating Market Entry

For stakeholders researching the mycoplasma testing market, this report benchmarks market share, segment-level pricing, and forecast data — by product & service, technique, application, end user, and region — to support sourcing, investment, and go-to-market decisions. It is built for procurement teams comparing suppliers, investors sizing entry points, and strategy teams tracking contract research organizations as a growth adjacency.

More Trending Latest Reports By Polaris Market Research:

Subscriber Data Management Market

Clinical Trial Patient Recruitment Services Market

Bunion Correction System Market

Pad-mounted Switchgear Market

Clinical Trial Patient Recruitment Services Market

Solar Panels Market

Cumene Market

Relieve Chronic Pain with Acupuncture Needles Market

U.S. Property Management Services Market